Using past research to solve today’s global pandemic: The power of Nature archives
Sponsored by Springer NatureRecorded on 10/15/2020
Posted in Reference Works and Research
As the world continues to be impacted by the COVID-19 virus, the scientific and medical research communities continue to rely on past discoveries to inform effective treatments. How is archival research advancing COVID-19 research? In this 1-hour webinar, learn what content researchers are accessing and citing from the archives as they search for therapeutics and vaccines for COVID-19. Of particular importance today is research that directs activity around RNA, and its relevance concerning vaccine options.
Guest speaker Angela K. Eggleston, Senior Editor, Biology, Nature, will explore the intersection of RNA research and the Nature Archives as well as how it has benefitted its users. This webinar is intended to benefit librarians, editors, researchers, information managers across the university and healthcare sectors, and the latter part of this webinar will include a lively Q&A.
The long publishing history of Nature has allowed scientists to access the wealth of RNA research published in the 151 year history of the journal. Nature has invested in preserving research by digitizing content from across the spectrum, and the Nature archives have played an important role in expediting publishing practices to meet global demands for a COVID-19 vaccine.
Angela K. Eggleston, Ph.D.Senior Editor and Biology Team LeaderNature
Angela Eggleston received her B.S. in microbiology and M.S. in molecular genetics from the University of Notre Dame, in South Bend, IN. She received her Ph.D. in biochemistry and molecular biology, from Northwestern University Medical School in Chicago, IL. Her doctoral studies concerned the role of the E. coli RecBCD helicase/nuclease in the initiation of genetic recombination and resulted in a U.S. patent. For her postdoctoral studies, she decamped to England and joined the Clare Hall Laboratories of the Imperial Cancer Research Fund (now Cancer Research UK). There she studied the opposite end of the recombination process, characterizing the E. coli RuvABC Holliday junction resolution complex. Her postdoctoral work was sponsored in part by a Burroughs-Wellcome Fund Hitchings-Elion Fellowship. She then undertook a short postdoctoral position at Children’s Hospital in Boston, MA, working on non-homologous end joining in mammalian cells. Following this, she entered the realm of scientific publishing, joining the Nature Publishing Group in October 1999 as an Associate Editor for Nature Cell Biology, traveling back to London to do so. In July 2001, she moved to Cell Press in Cambridge, MA as a Senior Editor, handling manuscripts for Cell, Molecular Cell, and Developmental Cell. In September 2003, she returned to Nature Publishing Group (now Springer Nature) as a Senior Editor for Nature, where she handles manuscripts on nucleic acid metabolism and synthetic biology; the biochemistry and biophysics of motor proteins and photosynthesis; and protein folding, engineering, and design. In 2006 she was made a Biological Sciences Team Leader, and in 2020 was advanced to be a Team Manager.
Impacts of COVID-19: How STI systems responded to the crisis, and the challenges that lie ahead
Sponsored by OECD
Impacts of COVID-19 and the Outlook for an Economic Recovery in 2021 – Insights from the OECD
Sponsored by OECD
Science, the press, and the public: Working with authors to convey research results
Sponsored by American Association for the Advancement of Science